Role of debulking surgery in combination with immune therapy: A successfully treated case of locally advanced mucosal melanoma

Kimura,Takahiro; Takahama,Takayuki; Wakasa,Tomoko; Adachi,Shiori; Akashi,Yusaku; Tamura,Takao; Yane,Katsunari

doi:10.3892/mco.2021.2435

Role of debulking surgery in combination with immune therapy: A successfully treated case of locally advanced mucosal melanoma

Authors:
- Takahiro Kimura
- Takayuki Takahama
- Tomoko Wakasa
- Shiori Adachi
- Yusaku Akashi
- Takao Tamura
- Katsunari Yane
View Affiliations

Affiliations: Department of Otorhinolaryngology, Kindai University Nara Hospital, Ikoma, Nara 630‑0293, Japan, Department of Medical Oncology, Kindai University Nara Hospital, Ikoma, Nara 630‑0293, Japan, Department of Diagnostic Pathology, Kindai University Nara Hospital, Ikoma, Nara 630‑0293, Japan
Published online on: November 4, 2021 https://doi.org/10.3892/mco.2021.2435
Article Number: 2

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Immune checkpoint inhibitors (ICIs) have markedly changed the treatment landscape for melanoma; however, their efficacy and applications are currently limited and medical requirements remain unmet. The present case study reports on a 85‑year‑old female patient who visited our outpatient clinic with a 1‑month history of a buccal mucosa mass and was diagnosed with locally advanced mucosal melanoma of the head and neck. The patient's tumor progressed right after the administration of nivolumab, compromising oral intake. Palliative debulking surgery was performed. Subsequently, the other part of the melanoma on the hard palate slightly decreased in size without forming new lesions for more than one year after surgery. The present case exemplifies that tumor volume reduction surgery may increase the response to ICI and may prolong the duration of response. This combination therapy may be more effective in patients whose tumors increase in size after administration of ICIs or whose tumor is already large at the beginning of treatment. The combination of ICIs and debulking surgery may become an important treatment option in the future for locally advanced mucosal melanoma.

View Figures

View References

1	Gray-Schopfer V, Wellbrock C and Marais R: Melanoma biology and new targeted therapy. Nature. 445:851–857. 2007.PubMed/NCBI View Article : Google Scholar
2	Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, et al: Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 372:30–39. 2015.PubMed/NCBI View Article : Google Scholar
3	Tucker MA: Melanoma epidemiology. Hematol Oncol Clin North Am. 23:383–395. 2009.PubMed/NCBI View Article : Google Scholar
4	Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 364:2517–2526. 2011.PubMed/NCBI View Article : Google Scholar
5	Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al: Combined nivolumab and ipilimumab or monotherapy in untreated Melanoma. N Engl J Med. 373:23–34. 2015.PubMed/NCBI View Article : Google Scholar
6	Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, et al: Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 372:320–330. 2015.PubMed/NCBI View Article : Google Scholar
7	D'Angelo SP, Larkin J, Sosman JA, Lebbé C, Brady B, Neyns B, Schmidt H, Hassel JC, Hodi FS, Lorigan P, et al: Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: A pooled analysis. J Clin Oncol. 35:226–235. 2017.PubMed/NCBI View Article : Google Scholar
8	Ozaki Y, Shindoh J, Miura Y, Nakajima H, Oki R, Uchiyama M, Masuda J, Kinowaki K, Kondoh C, Tanabe Y, et al: Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: A case report. BMC Cancer. 17(778)2017.PubMed/NCBI View Article : Google Scholar
9	López F, Rodrigo JP, Cardesa A, Triantafyllou A, Devaney KO, Mendenhall WM, Haigentz M Jr, Strojan P, Pellitteri PK, Bradford CR, et al: Update on primary head and neck mucosal melanoma. Head Neck. 38:147–155. 2016.PubMed/NCBI View Article : Google Scholar
10	Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, et al: Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 377:1345–1356. 2017.PubMed/NCBI View Article : Google Scholar
11	Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, Xu W, Harmon S, Giles JR, Wenz B, et al: T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 545:60–65. 2017.PubMed/NCBI View Article : Google Scholar
12	Guisier F, Cousse S, Jeanvoine M, Thiberville L and Salaun M: A rationale for surgical debulking to improve anti-PD1 therapy outcome in non small cell lung cancer. Sci Rep. 9(16902)2019.PubMed/NCBI View Article : Google Scholar
13	Joseph RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, et al: Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab. Clin Cancer Res. 24:4960–4967. 2018.PubMed/NCBI View Article : Google Scholar
14	Liu Y, Dong Y, Kong L, Shi F, Zhu H and Yu J: Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. J Hematol Oncol. 11(104)2018.PubMed/NCBI View Article : Google Scholar
15	Oronsky B, Larson C, Reid TR and Carter CA: Case series: Abscopal benefit of surgery in 3 immunotherapy-treated patients with unresectable cancer. J Investig Med High Impact Case Rep: Jul 6, 2018 (Epub ahead of print). doi: 10.1177/2324709618786319.
16	Eggermont AMM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, et al: Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 375:1845–1855. 2016.PubMed/NCBI View Article : Google Scholar
17	Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, et al: CheckMate 238 collaborators. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 377:1824–1835. 2017.PubMed/NCBI View Article : Google Scholar
18	Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, et al: adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 378:1789–1801. 2018.PubMed/NCBI View Article : Google Scholar